11:00 CET

Webcast – present and explain melflufen’s mechanism of action

Oncopeptides will host a webcast on Monday, January 27th 2020 were CEO Jakob Lindberg will present and explain melflufen’s mechanism of action.

 

Conference call for investors, analysts and the media, Monday, January 27th 2020, at 11 (CET)

 

Phone numbers for participants from:
Sweden: +46 8 56642651
Europe: +44 6319131422
USA: +1 3333000804

Participant Pin code
PIN: 84274870#

The conference call will also be streamed via the link below:
https://tv.streamfabriken.com/2020-01-27-oncopeptides-press-conference

The presentation will be available under Presentations just before the start of the webcast:
www.oncopeptides.com / Investor Relations / Presentations / Presentation webcast melflufen mechanism-of-action/

Upcoming events

Silent Period

-

FDA - Oncologic Drugs Advisory Committee (ODAC) Meeting

The US Food and Drug Administration, FDA, has announced a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (ODAC), on October 28, 2021 concerning Oncopeptides’ product Pepaxto. The information is in line with the FDA safety alert on July 28, where the FDA stated that a public meeting may be hold to discuss the safety findings from the OCEAN study.

Interim Report Q3 2021

08:00 CET

63rd ASH Annual Meeting & Exposition

-

American Society of Hematology (ASH) 63rd annual meeting with both in-person and virtual participation at the Georgia World Congress Center in Atlanta, Georgia. ASH Annual Meeting & Exposition is the largest event in malignant and non-malignant hematology.

Silent Period

-

Year-end report 2021

08:00 CET

Silent Period

-

Silent Period

-